X4 Pharmaceuticals Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" X4 Pharmaceuticals stock.
View analyst ratings for X4 Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given X4 Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but X4 Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

X4 Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 590,400 shares, an increase of 61.7% from the June 30th total of 365,100 shares. Based on an average daily volume of 225,800 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.9% of the company's stock are short sold.
View X4 Pharmaceuticals' Short Interest.

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for X4 Pharmaceuticals.

X4 Pharmaceuticals will be holding an earnings conference call on Tuesday, August 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its quarterly earnings data on Thursday, May, 6th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.46.
View X4 Pharmaceuticals' earnings history.

X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XFOR stock has decreased by 30.0% and is now trading at $6.01.
View which stocks have been most impacted by COVID-19.

6 brokers have issued 1-year price objectives for X4 Pharmaceuticals' stock. Their forecasts range from $15.00 to $27.00. On average, they expect X4 Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 232.8% from the stock's current price.
View analysts' price targets for X4 Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to X4 Pharmaceuticals include DBV Technologies (DBVT), Talaris Therapeutics (TALS), Precision BioSciences (DTIL), Adaptimmune Therapeutics (ADAP), Aligos Therapeutics (ALGS), Poseida Therapeutics (PSTX), TCR2 Therapeutics (TCRR), Soaring Eagle Acquisition (SRNG), Compugen (CGEN), Tarsus Pharmaceuticals (TARS), Outlook Therapeutics (OTLK), Lineage Cell Therapeutics (LCTX), Oyster Point Pharma (OYST), Ikena Oncology (IKNA) and Codiak BioSciences (CDAK).
View all of XFOR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

X4 Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Minot Wealth Management LLC (0.07%). Company insiders that own X4 Pharmaceuticals stock include Adam S Mostafa, Derek M Meisner, Paula Ragan and Renato Skerlj.
View institutional ownership trends for X4 Pharmaceuticals.

XFOR stock was purchased by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC.
View insider buying and selling activity for X4 Pharmaceuticals or or view top insider-buying stocks.

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XFOR stock can currently be purchased for approximately $6.01.

X4 Pharmaceuticals has a market capitalization of $148.85 million and generates $3 million in revenue each year. The company earns $-62,130,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.

X4 Pharmaceuticals employs 75 workers across the globe.

The official website for X4 Pharmaceuticals is www.x4pharma.com.

X4 Pharmaceuticals is headquartered at 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139.

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]